The advent of chimeric antigen receptor (CAR)-T cell therapy has marked the onset of a very promising option to treat solid tumors after its remarkable ...

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

Summary • Pfizer’s stock is up 1.8% to $26.305 during intraday trading, driven by recent collaborative agreements.• Agreements with Adaptive Biotechnologies focus on T-cell receptor discovery and data ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...

AstraZeneca plc (Nasdaq: AZN) is sharply expanding its ambitions in hematology and cell therapy, unveiling new clinical data ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

By manipulating this pathway, scientists may be able to tweak the immune response to treat cancers, autoimmune disorders, and more.

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...

A molecule involved in red blood cell production determines whether the immune system attacks or ignores cells in the body via peripheral immune tolerance, Stanford Medicine-led research finds.

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...